Sumitomo Pharma company profile
Company profile
Sumitomo Pharma has 4,980 employees and is headquartered in Osaka, Japan.
Pharmaceutical manufacturing and sales form the core of Sumitomo Pharma's operations, covering prescription medicines for neurological and metabolic conditions, women's health and overactive bladder. Its range also includes atypical antipsychotics, generic drugs, antiepileptic medicines, carbapenem antibiotics and treatments for pediatric congenital athymia. The group sells veterinary medicines and medical devices in Japan, North America and Asia, and it works with Otsuka Pharmaceutical under a collaboration and license agreement.
In the fiscal year ended March 31, 2026, revenue reached 453.3 billion yen, up 13.7% from the previous year, and net income came to 106.9 billion yen. The company has 4,980 employees. It was founded in 1897 and is headquartered in Osaka, Japan. It took its current name in April 2022, when it was known as Sumitomo Dainippon Pharma, and it is a subsidiary of Sumitomo Chemical Company, Limited.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Japan
- Headquarters
- 2-6-8 Doshomachi, 541-0045, Osaka
- Employees
- 4,980
- Chief executive
- Toru Kimura
- Founded
- 1897
- Fiscal year
- April - March
- Listing
- 4506 · TSE
- Indices
- Nikkei 225
- Currency
- JPY
- ISIN
- JP3495000006
- Website
- sumitomo-pharma.com
Sumitomo Pharma and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Sumitomo Pharma4506 | Japan | $5.69B | 4,980 | -0.4% | 19.2 |
| Kyowa Kirin4151 | Japan | $8.46B | 5,161 | 21.8% | 16.6 |
| Eisai4523 | Japan | $9.14B | 10,543 | 6.7% | 33.3 |
| CiplaCIPLA | India | $11.93B | 31,369 | 13.0% | 38.8 |
| Zhejiang NHU002001 | China | $12.3B | 11,508 | 33.8% | 10.9 |
| Zydus LifesciencesZYDUSLIFE | India | $12.59B | 29,980 | 17.2% | 28.4 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
